A meta-analysis was performed on the reported literature regarding followings. First, values of the MichaelisMenten constants (K m ), maximal velocities (V max ), and intrinsic clearance (V max /K m ) and the metabolic activities mediated by human cytochrome P450 3A4 and/or 3A5; second, inhibition constants (K i ); and third, maximum inactivation rate constants (k inact ) to establish the contribution of P450 3A5 to drug metabolism. At least 120 of the 127 metabolic reactions investigated (> 94%) were catalyzed by P450 3A4 and by P450 3A5. In the 73 metabolic reactions for which data were available, the mean P450 3A5/P450 3A4 ratios of K m , V max , and V max /K m values were 1.93, 1.25, and 1.20, respectively, but the median ratios were 1.17, 0.64, and 0.56, respectively. In 14-18% of the metabolic reactions, the V max and V max /K m values for P450 3A5 were more than twice those for P450 3A4. The K i values for P450 3A5 were on average approximately 5 times those for P450 3A4. Five of 13 mechanism-based inhibitors of P450 3A4 (38%) did not exhibit similar mechanism-based inhibition of P450 3A5. These collective findings give insight into the contribution of polymorphic P450 3A5 to drug metabolism and adverse drug interactions.
INTRODUCTION
Cytochrome P450 (P450 or CYP) 3A is the most important human P450 subfamily due to its high relative abundance in the liver and broad substrate specificity. [1] [2] [3] CYP3A4 is generally thought to be the predominant form expressed in the human liver and intestine, whereas CYP3A5, which is expressed polymorphically, might contribute as much as 50% of hepatic CYP3A in a third of Caucasians and in one half of African-Americans. 4) Since CYP3A5 and CYP3A4 are 83% homogeneous in terms of amino acid sequence, it is believed that the substrate specificity of CYP3A5 is similar to that of CYP3A4; however, certain differences in catalytic properties have been demonstrated. 2, 5) Similarly, many of the inhibitors of CYP3A4 are reported to also inhibit CYP3A5 activities. 6 Recently we summarized the reported values of the Michaelis-Menten constants (K m ), maximal velocities (V max ), and intrinsic clearance (V max /K m ) mediated by CYP3A4 and/or CYP3A5, as well as the inhibition constants (K i ), 50% inhibitory concentrations (IC 50 ), and maximum inactivation rate constants (k inact ), and demonstrated that while the substrate specificities of CYP3A4 and CYP3A5 generally overlap, they are somewhat different. 7) However, there are few reports that compare in detail the kinetic parameters for drug oxidation and the substrate inhibition potential of metabolic reactions mediated by CYP3A4 and CYP3A5.
In this review, values for metabolic activities taken from the literature are compared in addition to the kinetic parameters to predict the relative contribution of CYP3A5. The kinetic parameters used in this study were taken from the review submitted in 2007 by us 7) as well as from more recent reports. For drug oxidation rates, a comprehensive literature search was performed to investigate the K m (µM), V max (nmol/min per nmol P450), and/or V max /K m (ml/min per nmol P450) values for recombinant ex-Vol. 56 (2010) pressed CYP3A4 or CYP3A5. Because only full kinetic profiles provide detailed information on the affinity of an enzyme for particular compounds, the metabolic activities of CYP3A4 and CYP3A5 were investigated separately from these kinetic parameters. In this article, the literature comparing metabolic activities was also investigated; this was not the case in our previous review. 7) Kinetic parameters estimated by substrate deletion activities were excluded. It was mostly the case that: data were generated with baculovirus-infected insect cells (e.g., Supersomes or Baculosomes) or Escherichia coli expressing CYP3A4 or CYP3A5, it was not stated whether cytochrome b 5 was added or how much CYP reductase was coexpressed, or estimation of the free fraction in microsomal incubation was not carried out. For inhibition potency, K i and k inact , but not IC 50 , were investigated. When the desired CYP3A5/CYP3A4 ratios were not given, the corresponding ratios were calculated from the kinetic parameters given in the article.
METABOLIC ACTIVITY OF CYP3A4 AND CYP3A5
Seven metabolic reactions have been shown to be catalyzed by CYP3A4 but not by CYP3A5, and 6 of the 7 reactions were hydroxylation (Table 1) . [8] [9] [10] [11] [12] However, in these reactions, a minor contribution of CYP3A5 may be demonstrated in the future when detection methods for the metabolite have been improved. In contrast, reactions which are predominantly catalyzed by CYP3A5 have not been reported.
The K m , V max , and V max /K m values for metabolic reactions mediated by CYP3A5 were compared with those mediated by CYP3A4 (Table 2). The kinetic parameters of 73 metabolic reactions (56 substrates) catalyzed both by CYP3A4 and by CYP3A5 have been reported. For these 73 (Table 3) . [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] The mean (± S.D.) and median CYP3A5/CYP3A4 ratios of the metabolic activities in these 47 reactions were 0.69 ± 1.23 and 0.28, respectively. Among the psychotropic drugs, both the V max and K m values of CYP3A5 for the 1 -hydroxylation of alprazolam and midazolam were more than twice those of CYP3A4; however, the V max /K m values of CYP3A5 were comparable with or higher than those of CYP3A4 (Table 2 ). In contrast, the K m values, but not the V max values, of CYP3A5 for the 1 -hydroxylation of triazolam and 4-hydroxylation of alprazolam, midazolam, and triazolam, were comparable with those of CYP3A4, and the V max /K m values of CYP3A5 were comparable with those of CYP3A4, except that the V max /K m value of CYP3A5 for midazolam 4-hydroxylation was lower than that of CYP3A4. Thus, differences in affinity and metabolic capacity do not appear to depend on the chemical structures of the substrate and/or the reaction position.
The V max /K m values for anticancer drugs mediated by CYP3A5 are comparable with or greater than those mediated by CYP3A4. In contrast, most of the V max and V max /K m values for dehydrogenation of many of the dihydropyridine calcium antagonists, such as benidipine, felodipine, and nifedipine, and steroid hydroxylation, such as testosterone 6β-hydroxylation and estradiol 2-or 4-hydroxylation, mediated by CYP3A5, are lower than those mediated by CYP3A4, whereas the K m values for CYP3A5 are higher than those for CYP3A4. 20, [27] [28] [29] 41) Similarly, the CYP3A5- 53) Bold: The ratio of the parameters for CYP3A5 and CYP3A4 was less than 0.5 times or more than 2 times. a) Benidipine, felodipine, nifedipine, and nitrendipine. b) Testosterone, estradiol, and 5-cholestane-3,7,12-triol. Values in parentheses show the range (minimum -maximum). HMG: 3-hydroxy-3-methylglutaryl, PPARr: peroxisome proliferator activated receptor, BFC: 7-benzoxy-4-trifluoromethylcoumarin, DBF: dibenzylfluorescein. catalyzed hydroxylation of atorvastatin had a higher K m and lower V max than the CYP3A4-catalyzed hydroxylation of atorvastatin, resulting in a lower V max /K m values for CYP3A5. Of interest, the V max /K m values of vincristine dehydrogenation and KR-63198 hydroxylation by CYP3A5 were more than 10 times those for CYP3A4. 26, 38) The effects of cytochrome b 5 on the metabolic activities of CYP3A4 and CYP3A5 are summarized in Table 4 . 26, 32, 34, 36) For most of the metabolic reactions, the CYP3A5/CYP3A4 ratios of K m , V max , and V max /K m values seem to not be markedly influenced by the addition of cytochrome b 5 . For example, with or without cytochrome b 5 , the V max and V max /K m values of CYP3A5 for the formation of a secondary amine (M1) from vincristine were 7-9 and 9-14 times, respectively, those of CYP3A4, while the K m values of CYP3A5 and CYP3A4 were comparable. 26) The CYP3A5/CYP3A4 ratios of K m , V max , and V max /K m values and metabolic activity were classified into six groups (Fig. 1) ; 0 (no activity by CYP3A5), less than 0.1 (CYP3A5 CYP3A4), between 0.1 and 0.5 (CYP3A5 < CYP3A4), between 0.5 and 2 (CYP3A5 ≈ CYP3A4), between 2 and 10 (CYP3A5 > CYP3A4), and more than 10 (CYP3A5 CYP3A4). At least 120 of 127 metabolic reactions investigated (94%) appeared to be catalyzed by both CYP3A4 and CYP3A5. For these metabolic reactions, 36-49% of the K m , V max , and V max /K m values for the reactions mediated by CYP3A5 were comparable with those mediated by CYP3A4. Interestingly, 14-18% of V max and V max /K m values for CYP3A5 were more than twice those for CYP3A4.
Fifty-seven of the 73 metabolic reactions for which kinetic parameters were available (78%) were hydroxylation or dealkylation reactions. When the hydroxylation or dealkylation reactions were analyzed separately, 52% of the dealkylation reactions and 34% of hydroxylation reactions had CYP3A5/CYP3A4 ratios of V max /K m and metabolic activities of more than 0.5. In particular, 42% of dealkylation reactions and 20% of hydroxylation reactions had CYP3A5/CYP3A4 ratios of metabolic activities of more than 0.5. Overall, 38% of the hydroxylation reactions had K m values 58) Cancer chemotherapy 73) Bold: The ratio of the activities of CYP3A5 and CYP3A4 was less than 0. 36) Bold: The ratio of the parameters for CYP3A5 and CYP3A4 was less than 0.5 times or more than 2 times. +C: Coexpressed b 5 , +E: Exogenous b 5 .
Fig. 1. Comparison of the Contributions of CYP3A4 and CYP3A5 to Drug Oxidation Rates
Ratios for CYP3A5/CYP3A4 were classified in six groups: 0 ( ), ≤ 0.1 ( ), 0.1-0.5 ( ), 0.5-2 ( ), 2-10 ( ), and ≥ 10 ( ). a) The reactions for which the metabolic activity was reported, but not the kinematic parameters, include those catalyzed by CYP3A4 but not by CYP3A5 (see Table 1 ).
for CYP3A5 that were more than twice those for CYP3A4, whereas the figure for dealkylation reactions was 22%.
INHIBITION OF CYP3A4 AND CYP3A5
The observed K i of CYP3A4 and CYP3A5 are summarized in Table 5 . 6, 50, 74, 75) Although inhibition by ketoconazole and diltiazem was investigated for the 1 -hydroxylation and 4-hydroxylation of midazolam, there were no marked differences among the estimated K i values between the metabolic reactions. For both CYP3A4 and CYP3A5, inhibition by ketoconazole and trans-resveratrol was noncompetitive, whereas inhibited by erythromycin, diltiazem, and nicardipine was competitive. The mean/median K i values for CYP3A5 of the 6 inhibitors were 5.0 ± 3.9 (mean ± S.D.) and 4.08 (median) times those for CYP3A4. However, the CYP3A5/CYP3A4 ratios of K i values for azole antifungals and calcium channel blockers were more than 3, whereas the K i values for CYP3A5 inhibited by erythromycin and trans-resveratrol were comparable with those for CYP3A4. 
Antibiotics, macrolides 
MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5
Mechanism-based inhibition of CYP3A4 by drugs is due to the chemical modification of the heme, the protein, or both as a result of covalent binding of modified heme to protein. 76) Important kinetic parameters for mechanism-based inhibition, such as k inact and the apparent K i , are determined using in vitro models. 76) Time-dependent inhibition by erythromycin, troleandomycin, saquinavir, raloxifene, tamoxifen, and N-demethyltamoxifen using midazolam 1 -hydroxylation and/or testosterone 6β-hydroxylation as the marker reactions, has been observed for CYP3A4 but not for CYP3A5 (Table 6) ; 41, [77] [78] [79] time-dependent inhibition of CYP3A5 but not of CYP3A4, however, has not been reported.
The k inact , K i , and k inact /K i values for CYP3A4 and CYP3A5 are summarized in Table 7 . 6, 77, 80) The k inact and k inact /K i values of CYP3A5 for the 8 inhibitors, other than nelfinavir, were lower than those of CYP3A4. The K i values of CYP3A5 for lopinavir and diltiazem were higher than those of CYP3A4. Five of the 13 inhibitors investigated (38%) did not exhibit mechanism-based inhibition of CYP3A5 (Tables 6 and 7) .
CONCLUSIONS AND PERSPECTIVES
At least 120 of the 127 metabolic reactions investigated (> 94%) were evidently catalyzed by both CYP3A4 and CYP3A5, indicating the impor- 6) reported that erythromycin is a mechanism-based inhibitor of CYP3A5. Bold: The ratio of the parameters for CYP3A5 and CYP3A4 was less than 0.5 times or more than 2 times.
tance of CYP3A5 in addition to CYP3A4. A new method for evaluating the contribution of CYP3A5 using metabolic activity classified into six groups ( Fig. 1 ) was introduced in this study. In particular, 14-18% of the V max and V max /K m values estimated for CYP3A5 were more than twice those for CYP3A4, and the V max /K m values of vincristine dehydrogenation and KR-63198 hydroxylation by CYP3A5 were more than 10 times those for CYP3A4. 26, 38) These results, shown in Fig. 1 , strongly suggest the importance of CYP3A5 in metabolism in the human liver and intestine, especially in hydroxylation reactions. The relative contribution of CYP3A5 compared with CYP3A4 varies independently of the chemical structure and the reaction positions of the substrates. High molecular weight also seems not to be a major factor affecting the CYP3A5/CYP3A4 ratios, because the ratios for the kinetic parameters of cyclosporine A (molecular weight: 1203) were different from those of tacrolimus (molecular weight: 804). In addition, there were no marked differences in the CYP3A5/CYP3A4 ratios for the kinetic parameters between hydroxylation and dealkylation reactions. Bu 3) reported that a low K m or V max /K m lipophilicity correlation, but not V max lipophilicity correlation, is exhibited for the 215 CYP3A4-mediated reactions of 113 drugs, suggesting a high degree of difficulty in predicting the kinetic parameters of CYP3A4 and of CYP3A5 from the chemical structure of the substrate. In addition, it has been shown that the experimental conditions, including the types of CYP3A4/5 expression system used, affect the relative contributions. Therefore, it is obviously difficult to predict the relative contributions of CYP3A5 and CYP3A4 from only the chemical structure and the physicochemical parameters (e.g., the lipophilicity and acid dissociation constant (pKa)) of the substrate and/or the reaction position. Further studies of molecular structure with three-dimensional chemical structure analysis of substrates and P450 proteins will be required to enable such prediction in the future.
The V max /K m and V max values for the dehydrogenation of many dihydropyridine calcium antagonists, including nifedipine, are lower for CYP3A5 than for CYP3A4, whereas the K m values for CYP3A5 are higher than CYP3A4. 20, [27] [28] [29] 41) In a clinical study it was demonstrated that the CYP3A5 genotype did not exert an impact on nifedipine disposition in healthy volunteers. 81) In contrast, it is of interest to note that vincristine is preferen-tially metabolized to a secondary amine (M1) by CYP3A5 with a V max /K m value 9-14 times that for CYP3A4. 26) In addition, the estimated hepatic clearances in liver microsomes from CYP3A5 high expressers are 5 times those from low expressers, suggesting that polymorphic expression of CYP3A5 may be a major determinant in the P450-mediated clearance of vincristine. 82) Recently, the importance of CYP3A5 expression was reportedly confirmed in human cryopreserved hepatocytes. 83) For most of the metabolic reactions considered here, the CYP3A5/CYP3A4 ratios of K m , V max , and V max /K m values were not markedly influenced by the addition of cytochrome b 5 , although an increase of the V max and/or V max /K m values was observed (Table 4) . On the other hand, the V max and V max /K m values for alprazolam 1 -hydroxylation by CYP3A5 appear to be at least twice those by CYP3A4 in the absence of cytochrome b 5 , 40) whereas the same phenomenon is not observed in the presence of cytochrome b 5 . 20) In addition, it has been reported that whether cytochrome b 5 is added by supplementation or coexpression also affects the metabolic activity. Ma et al. 53) reported that the t-butyl hydroxylation and N-demethylation activities of TPA023 obtained by cytochrome b 5 -coexpressed CYP3A5 are higher than those of cytochrome b 5 -supplemented CYP3A5. Similarly, CYP3A4 coexpressed with cytochrome b 5 results in higher catalytic activity toward ifosfamide Ndechloroethylation than that of cytochrome b 5 -supplemented CYP3A4; this effect was greater than that for CYP3A5. 25) Also, the V max and V max /K m values for alfentanil N-dealkylation by cytochrome b 5 -coexpressed CYP3A4 are higher than those for cytochrome b 5 -supplemented CYP3A4. 34) The V max /K m of quetiapine with cytochrome b 5 was less than 35% that of CYP3A4, and V max /K m for CYP3A4 without cytochrome b 5 was 3 times that of CYP3A4 with coexpressed cytochrome b 5 , whereas for CYP3A5, V max /K m was similar for both microsomal preparations. 66) Further detailed studies on the contribution of cytochrome b 5 are required in the future.
The V max and V max /K m values for many anti-infective agents, including macrolides (clarithromycin and erythromycin) and azole antifungals (fluconazole and itraconazole) mediated by CYP3A5 are lower than those mediated by CYP3A4. 12, 13, 20) CYP3A5 with or without cytochrome b 5 supplementation does not catalyze itraconazole hydroxylation, and significant metabolism of itraconazole into metabolic products is not observed. 12) Similarly, azole antifungal agents, including ketoconazole and fluconazole, are wellestablished potent noncompetitive inhibitors of CYP3A4, 2, 74, 84) but the K i values for CYP3A5 are approximately 4-9 times those for CYP3A4, although they are still in the nanomolar range. 2, 6, 74) In addition, the IC 50 values for the inhibition by azamulin, fluconazole, and ketoconazole of CYP3A5 are reported to be higher than those of CYP3A4. 7) This phenomenon is also observed for macrolide antibiotics (erythromycin and troleandomycin), antivirals (amprenavir and indinavir), calcium channel blockers (diltiazem and nicardipine), and antidepressants (fluoxetine, fluvoxamine, nafazodone, and trazodone); however, the IC 50 values for nelfinavir and ritonavir toward CYP3A5 are lower than those toward CYP3A4. 7) Erythromycin, diltiazem, and nicardipine are reported to be competitive inhibitors of both CYP3A4 and CYP3A5. Cyclosporine (0.62 µM) causes a 44% decrease of the V max /K m value of sirolimus depletion by CYP3A4 versus only an 8% decrease by CYP3A5. 31) Thus, it may be that the inhibition potency is related to the affinity and/or voracity of the inhibitor toward CYP3A4/5 in the oxidation reaction.
Five of the 13 inhibitors investigated (38%) did not exhibit mechanism-based inhibition of CYP3A5, and the k inact and k inact /K i values of CYP3A5 for 7 of the other 8 inhibitors were lower than those of CYP3A4 (Tables 6 and 7) . Mechanism-based inhibition of the metabolism catalyzed by CYP3A4 rather than CYP3A5 for diltiazem has been demonstrated to occur primarily by the formation of a metabolite intermediate complex with P450. 19) Some clinical studies have demonstrated that CYP3A5 is of minimal importance in terms of the overall CYP3A metabolic phenotype for some CYP3A substrates, such as midazolam, [85] [86] [87] [88] alfentanil, 88) and saquinavir. 89) However, the present information suggests the following: the relative contribution of polymorphic CYP3A5 to the metabolism of CYP3A4/5 substrates, especially in hydroxylation reactions, is significant, and the risk of adverse drug-drug interactions due to competitive and/or mechanism-based inhibition mediated by CYP3A5 is lower than that mediated by CYP3A4, although the limitations of this study should be considered when interpreting the results. The causal factor(s) and reasons for the different findings for the kinetic parameters and inhibi-tion constants should be determined in future drug metabolism and drug interaction studies. In addition, it is suggested that further clinical research will be necessary to confirm the contribution of polymorphic CYP3A5 relative to that of abundant CYP3A4.
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